Tezosentan
-
Tezosentan
structure -
-
CAS No:
180384-57-0
-
Formula:
C27H27N9O6S
-
Chemical Name:
Tezosentan
-
Synonyms:
2-Pyridinesulfonamide,N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)-;2-Pyridinesulfonamide,N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)-;N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)-2-pyridinesulfonamide;Tezosentan;RO 610612;ACT 050089;N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide;Ro 61-6612
-
CAS No:
Description
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
Drug Information
Investigated for use/treatment in congestive heart failure, liver disease, and heart disease.
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
A pronounced and rapid disposition phase (half-life 6 min), accounting for the major part of the elimination, was followed by a slower phase (half-life 3 h), probably caused by distribution from tissues.
5-isopropyl-pyridine-2-sulfonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl--pyridin-4-yl)--pyrimidin-4-ylamide
Computed Properties
Molecular Weight:605.6
XLogP3:2.4
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:14
Rotatable Bond Count:12
Exact Mass:605.18050079
Monoisotopic Mass:605.18050079
Topological Polar Surface Area:209
Heavy Atom Count:43
Complexity:962
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Request for Quotation